| Literature DB >> 26673551 |
Hidetaka Wakabayashi1, Masato Matsushima2, Rimiko Uwano3, Naoko Watanabe3, Hideyuki Oritsu3, Yoshitaka Shimizu3.
Abstract
BACKGROUND: The purpose of this study was to assess the association between skeletal muscle mass, activities of daily living (ADLs) and severe dysphagia in cancer patients.Entities:
Keywords: Carcinoma; Nutrition; Rehabilitation; Sarcopenia; Sarcopenic dysphagia
Year: 2015 PMID: 26673551 PMCID: PMC4670744 DOI: 10.1002/jcsm.12052
Source DB: PubMed Journal: J Cachexia Sarcopenia Muscle ISSN: 2190-5991 Impact factor: 12.910
Results of comparative tests for differences between subjects categorized by the severity of dysphagiaa
| Total | Non-oral feeding | Oral food intake | ||
|---|---|---|---|---|
| Age, years | 70 ± 10 | 73 ± 10 | 68 ± 10 | 0.013 |
| Sex, | 0.778 | |||
| Male | 86 (77%) | 25 (76%) | 61 (78%) | — |
| Female | 25 (23%) | 8 (24%) | 17 (22%) | — |
| Cancer types | ||||
| Esophageal or pharyngeal | 57 (51%) | 11 (33%) | 46 (59%) | 0.013 |
| Others | 54 (49%) | 22 (67%) | 32 (41%) | — |
| Cancer stage, | 0.287 | |||
| 1 | 20 (19%) | 4 (13%) | 16 (22%) | — |
| 2 | 19 (18%) | 5 (16%) | 14 (19%) | — |
| 3 | 39 (37%) | 11 (34%) | 28 (38%) | — |
| 4 | 27 (26%) | 12 (38%) | 15 (21%) | — |
| Cancer treatment | <0.001 | |||
| Surgery | 71 (64%) | 13 (39%) | 58 (74%) | — |
| Without surgery | 40 (36%) | 20 (61%) | 20 (26%) | — |
| Psoas muscle area, cm2 | 14.2 ± 5.1 | 12.7 ± 4.7 | 14.9 ± 5.1 | 0.038 |
| Male | 15.5 ± 5.0 | 14.1 ± 4.7 | 16.1 ± 5.0 | 0.106 |
| Female | 10.4 ± 3.0 | 9.1 ± 2.9 | 10.9 ± 3.0 | 0.185 |
| Skeletal muscle index, cm2/m2 | 5.40 ± 1.72 | 5.00 ± 1.73 | 5.56 ± 1.69 | 0.129 |
| Male | 5.68 ± 1.74 | 5.23 ± 1.77 | 5.85 ± 1.72 | 0.161 |
| Female | 4.43 ± 1.21 | 4.24 ± 1.46 | 4.51 ± 1.12 | 0.185 |
| Presarcopenia | 52 (50%) | 18 (60%) | 34 (45%) | 0.174 |
| Male | 45 (55%) | 16 (70%) | 29 (49%) | 0.095 |
| Female | 7 (30%) | 2 (29%) | 5 (31%) | 1.000 |
| Vocal cord paralysis | 45 (43%) | 7 (33%) | 38 (52%) | 0.130 |
| Barthel index | 20 (0–65) | 0 (0-30) | 32 (5–74) | <0.001 |
| BMI | 21.0 ± 3.6 | 20.1 ± 3.4 | 21.3 ± 3.7 | 0.154 |
| Albumin, g/dL | 2.6 ± 0.6 | 2.4 ± 0.6 | 2.8 ± 0.6 | 0.003 |
| Haemoglobin, g/dL, | 9.9 ± 1.6 | 9.4 ± 1.8 | 10.1 ± 1.6 | 0.031 |
| CRP, mg/dL | 2.0 (1.0–4.5) | 3.0 (1.2–5.6) | 1.9 (0.8–4.3) | 0.206 |
| mGPS, | 0.323 | |||
| 0 | 28 (26%) | 21 (28%) | 7 (23%) | — |
| 1 | 4 (4%) | 4 (5%) | 0 (0%) | — |
| 2 | 74 (70%) | 50 (67%) | 24 (77%) | — |
| Number of days from admission to speech therapy | 18 (13–25) | 20 (15–32.5) | 17 (12–23) | 0.033 |
| Number of days from speech therapy to discharge | 31 (19–61) | 55 (24.5–111.5) | 30 (18–54) | 0.011 |
Values represent the mean ± SD for age, psoas muscle area, BMI, albumin, and haemoglobin and the median (25th–75th percentiles) for the Barthel Index, CRP, and number of days from admission to speech therapy and from speech therapy to discharge.
t-test.
Chi-squared test.
Mann–Whitney U test.
BMI, body mass index; CRP, C-reactive protein; mGPS, modified Glasgow Prognostic Score; SD, standard deviation.
Results of the Pearson correlation and Spearman rank correlation testsa
| Barthel index | BMI | Albumin | Haemoglobin | CRP | Age | |
|---|---|---|---|---|---|---|
| Skeletal muscle index | 0.021 | 0.508 | 0.038 | 0.086 | 0.009 | −0.127 |
| Barthel index | — | −0.021 | 0.326 | 0.246 | −0.113 | −0.145 |
| BMI | — | — | 0.137 | 0.190 | 0.024 | −0.253 |
| Albumin | — | — | — | 0.684 | −0.465 | −0.246 |
| Haemoglobin | — | — | — | — | −0.331 | −0.008 |
| CRP | — | — | — | — | — | 0.057 |
Statistically significant at P <0.05.
Values represent the Spearman rank correlation coefficients for the Barthel Index and CRP and the Pearson correlation coefficients for BMI, albumin, haemoglobin, and age.
BMI, body mass index; CRP, C-reactive protein.
Results of comparative tests for differences in skeletal muscle index and Barthel Index score in subjects categorized by sex, cancer stage, and modified Glasgow Prognostic Score
| Skeletal muscle index | Barthel index | |||
|---|---|---|---|---|
| Sex | <0.001 | — | 0.891 | |
| Male | 5.68 ± 1.74 | — | 20 (0–60) | — |
| Female | 4.43 ± 1.21 | — | 10 (0–86) | — |
| Cancer stage | 0.441 | 0.786 | ||
| 1 | 5.58 ± 1.57 | — | 20 (0–86) | — |
| 2 | 4.91 ± 1.58 | — | 10 (0–65) | — |
| 3 | 5.64 ± 1.78 | — | 29.5 (0–72) | — |
| 4 | 5.29 ± 1.67 | — | 7.5 (0–49) | — |
| mGPS | 0.655 | 0.048 | ||
| 0 | 5.17 ± 1.81 | — | 45 (0–92.5) | — |
| 1 | 5.53 ± 1.71 | — | 57 (31–72.5) | — |
| 2 | 5.25 ± 2.29 | — | 10 (0–52.5) | — |
| Multiple comparison test mGPS and Barthel index | ||||
| 0 vs. 1 | — | — | — | 0.495 |
| 0 vs. 2 | — | — | — | 0.043 |
| 1 vs. 2 | — | — | — | 0.103 |
Values represent the mean ± standard deviation.
Values represent the median (25th–75th percentiles).
t-test.
Mann–Whitney U test.
Analysis of variance.
Kruskal–Wallis test.
mGPS, modified Glasgow Prognostic Score.
Forced entry logistic regression analysis
| OR | 95% CI | |||
|---|---|---|---|---|
| Age | 1.378 | 0.194 | 9.777 | 0.749 |
| Sex | 1.033 | 0.949 | 1.126 | 0.451 |
| Skeletal muscle index | 1.829 | 1.107 | 3.022 | 0.018 |
| Barthel index | 1.019 | 0.997 | 1.042 | 0.098 |
| Albumin | 1.759 | 0.443 | 6.987 | 0.422 |
| Cancer stage 1 | 2.935 | 0.366 | 23.513 | 0.311 |
| Cancer stage 2 | 2.653 | 0.390 | 18.051 | 0.319 |
| Cancer stage 3 | 3.035 | 0.360 | 25.590 | 0.307 |
| Cancer types | 2.043 | 0.386 | 10.820 | 0.401 |
| Vocal cord paralysis | 1.572 | 0.403 | 6.129 | 0.515 |
| Constant | <0.001 | — | — | 0.072 |
OR, adjusted odds ratio.
CI, confidence interval.